Associated Papers
Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer.
Yang Z et al.
Npj Breast Cancer, 2023
37160904 (PubMed )
Supplement: 41523_2023_542_MOESM1_ESM.pdf
Select a paper to view details